Share on LinkedInShare on LinkedIn

ARTICLE · 01 SEPTEMBER 2023

DOJ Criminal Antitrust Settlements Involve Dollars, Donations, And Divestitures

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

On August 21, the U.S. Department of Justice (DOJ), Antitrust Division announced deferred prosecution agreements (DPAs) resolving criminal antitrust charges against Teva Pharmaceuticals USA Inc.

United StatesAntitrust/Competition Law

On August 21, the U.S. Department of Justice (DOJ), Antitrust Division announced deferred prosecution agreements (DPAs) resolving criminal antitrust charges against Teva Pharmaceuticals USA Inc. (Teva) and Glenmark Pharmaceuticals Inc., USA (Glenmark). The DPAs are historic. For the first time ever, a DOJ antitrust criminal settlement requires divestiture from a line of business and a donation of the allegedly price-fixed products to a third party.

The charges against Teva and Glenmark resulted from DOJ's broader criminal investigation into alleged price fixing by generic pharmaceutical companies. Teva and Glenmark were charged in 2020, and now represent the sixth and seventh companies to settle such charges with DOJ. Five other companies were charged in the investigation, all of which have entered deferred prosecution agreements. In addition, three individual executives have pleaded guilty, while another awaits trial.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from